Carlo Russo
Chief Medical Officer & Head of Development Genenta Science
Carlo Russo is a senior biotech executive with vast experience in research & development in large pharma companies and biotech industry with extensive expertise in clinical development in oncology, gene therapy, cardiovascular, metabolic diseases, infectious and rare diseases. A proven track record of bringing products through Phase 1-3 clinical development to regulatory approval.
He has served as Head of Development of GSK’s R&D Biopharm and Rare Disease Units, the Head of Cardiovascular Metabolic Center and the founder & Head of the Alternative Development Programs. He was Executive VP and CMO of Adverum, CMO & Head R&D of Annapurna and President and CEO of VaxInnate Corporation, among other senior roles. Carlo holds a number of senior positions at research institutions, including Cornell University Medical College, Columbia University and Scripps Research Institute. He holds his MD and Board Certification in Hematology from the University of Genoa Medical School and is the author of more than 70 scientific publications
Seminars
- Discussing the development of a novel cell therapy approach that uses modified macrophages to manipulate the tumor microenvironment in glioblastoma
- Highlighting the translation of a wild-type GBM strategy from the lab into a Phase 1 clinical trial, with a focus on how the therapy’s mechanism impacts patient outcomes
- Exploring the early-stage findings from this study and their implications for the future of GBM therapy, specifically through a patient-centric, immunotherapeutic approach
- Diving into the scientific breakthroughs in GBM immunotherapies including oncolytic viruses, cell therapies and bispecific antibodies to overcome immunosuppression in the brain
- Navigating the biomarker validation process in order to identify reliable and predictive biomarkers accurately assess the effect of immunotherapies for GBM
- Advancing clinical endpoints for immunotherapies to overcome challenges involved with pseudo-progression
